• Who we are

Our focus

Multispecific yet natural

We strongly believe that multispecific antibodies can only meet their full potential if they are well tolerated by the human body.

Taking advantage of the unique features of human antibody light chains, we have developed an approach to generate bispecific antibodies that fully retain the sequence and architecture of human antibodies.

They are therefore ideally suited for therapeutic applications, in particular if prolonged administration to patients is required.

First patient dosed with NILK-2301 in Phase I clinical trial

First-in-human trial of a CEACAM5xCD3 bispecific κλ body for solid cancer


Read more

LinkedIn